Finanzen von Alpha Tau Medical Ltd (DRTS)DRTSAlpha Tau Medical Ltd

Evaluating the bottom line, Alpha Tau Medical Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -141.68%, provide a clear picture of how effectively DRTS converts its operational activities into shareholder value.

In the context of the broader market, DRTS competes directly with industry leaders such as TNDM and ENOV. With a market capitalization of $1.13B, it holds a leading position in the sector. When comparing efficiency, DRTS's gross margin of N/A stands against TNDM's 56.11% and ENOV's 54.51%. Such benchmarking helps identify whether Alpha Tau Medical Ltd is trading at a premium or discount relative to its financial performance.

The company has shown a consistent decline in net income, with losses increasing to -45,813,000 USD in Q2 2026. The EPS has also worsened, reaching -0.50, indicating deteriorating financial performance.